Products: BC for Monoclonal Antibodies

MAbs: new therapeutic fields

MAbs represent new hope and new fast growing market. This research leads to new regulatory requirements in a fast growing pharmaceutical industry.

The monoclonal antibody market was worth 48 billion dollars in 2010 and is expected to grow annually by over 10% to reach nearly 60 billion dollars in 2014. Several monoclonal antibodies have become "Blockbusters", that is to say, with sales exceeding one billion dollars, including Remicade^® (Johnson & Johnson - $ 7.3 billion in 2010), Avastin ^® (Roche - $ 7.0 billion in 2010), Enbrel^® (Amgen & Pfizer - $ 6.5 billion in 2010), Humira ^® (Abbott Laboratories - $ 6.5 billion in 2010), Rituxan^® / MabThera^® (Roche, Genentech &Biogen - $ 6.8 billion in 2010) and Herceptin (Roche - $ 5.8 billion in 2010).

In 2008, the market shares of major pharmaceutical companies in the market for monoclonal antibodies were as follows: